Carpenter C C, Fischl M A, Hammer S M, Hirsch M S, Jacobsen D M, Katzenstein D A, Montaner J S, Richman D D, Saag M S, Schooley R T, Thompson M A, Vella S, Yeni P G, Volberding P A
Brown University School of Medicine, Providence, RI 02906, USA.
JAMA. 1997 Jun 25;277(24):1962-9.
To provide current recommendations for antiretroviral therapy for human immunodeficiency virus (HIV) disease.
The original International AIDS Society-USA 13-member panel representing international expertise in antiretroviral research and care of patients with HIV infection.
The following were considered: Newly available clinical and basic science study results, including phase 3 controlled trials; clinical, virological, and immunologic end-point data; interim analyses of studies presented at national and international research conferences; studies of HIV pathophysiology; and expert opinions of panel members. Recommendations were limited to the drugs available in mid 1997.
The full panel met on a regular basis (July 1996, September 1996, November 1996, January 1997, and April 1997) since the publication of its initial recommendations in mid 1996 to review new research reports and interim results. The panel discussed whether and how new information changed its initial recommendations. The recommendations contained herein were determined by group consensus.
New data have provided a stronger rationale for earlier initiation of more aggressive therapy than previously recommended and reinforce the importance of careful selection of initial drug regimen for each patient for optimal long-term clinical benefit and adherence. The plasma viral load is a crucial element of clinical management for assessing prognosis and the effectiveness of therapy, and such testing must be done properly. Treatment failure is most readily indicated by a rising plasma HIV RNA level and should be confirmed prior to a change of treatment. Therapeutic approaches must be updated as new data, particularly on the long-term clinical effect of aggressive antiretroviral treatment, continue to emerge.
提供关于人类免疫缺陷病毒（HIV）疾病抗逆转录病毒治疗的当前建议。
最初由13名成员组成的美国国际艾滋病学会小组，代表抗逆转录病毒研究及HIV感染患者护理方面的国际专业知识。
考虑了以下内容：新获得的临床和基础科学研究结果，包括3期对照试验；临床、病毒学和免疫学终点数据；在国内和国际研究会议上发表的研究的中期分析；HIV病理生理学研究；以及小组成员的专家意见。建议仅限于1997年年中可用的药物。
自1996年年中发布初始建议以来，整个小组定期开会（1996年7月、1996年9月、1996年11月、1997年1月和1997年4月），以审查新的研究报告和中期结果。小组讨论了新信息是否以及如何改变其初始建议。此处包含的建议由小组共识决定。
新数据为比先前建议更早开始更积极的治疗提供了更强有力的依据，并强化了为每位患者精心选择初始药物方案以实现最佳长期临床效益和依从性的重要性。血浆病毒载量是评估预后和治疗效果的临床管理的关键要素，此类检测必须正确进行。血浆HIV RNA水平升高最容易表明治疗失败，在改变治疗之前应予以确认。随着新数据不断涌现，特别是关于积极抗逆转录病毒治疗的长期临床效果的数据，治疗方法必须更新。
